دورية أكاديمية
أعرض في EDS

Evaluation of the CLL-IPI and IPS-E Prognostic Indices in a Young Middle Eastern Population with Chronic Lymphocytic Leukemia: A Retrospective Analysis at the Kuwait Cancer Control Center.

التفاصيل البيبلوغرافية
العنوان: Evaluation of the CLL-IPI and IPS-E Prognostic Indices in a Young Middle Eastern Population with Chronic Lymphocytic Leukemia: A Retrospective Analysis at the Kuwait Cancer Control Center.
المؤلفون: Alshemmari SH; Department of Medicine, Kuwait University, Jabriya, Kuwait.; Department of Hematology, Kuwait Cancer Center, Shuwaikh, Kuwait., Alsarraf A; Department of Hematology, Kuwait Cancer Center, Shuwaikh, Kuwait., Kunhikrishnan A; Department of Hematology, Kuwait Cancer Center, Shuwaikh, Kuwait., Pandita R; Department of Hematology, Kuwait Cancer Center, Shuwaikh, Kuwait.
المصدر: Medical principles and practice : international journal of the Kuwait University, Health Science Centre [Med Princ Pract] 2023; Vol. 32 (3), pp. 192-199. Date of Electronic Publication: 2023 Jul 28.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Karger Country of Publication: Switzerland NLM ID: 8901334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0151 (Electronic) Linking ISSN: 10117571 NLM ISO Abbreviation: Med Princ Pract Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel (Schweiz) ; New York : Karger, [1988-
مواضيع طبية MeSH: Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis , Leukemia, Lymphocytic, Chronic, B-Cell*/epidemiology, Humans ; Middle Aged ; Aged ; Prognosis ; Retrospective Studies ; Kuwait/epidemiology
مستخلص: Introduction: The Chronic Lymphocytic Leukemia International Prognostic Index (CLL-IPI) is a powerful prognostic tool validated in multiple Western populations. However, its utility in the young Middle Eastern population is unknown.
Methodology: We conducted a retrospective analysis of 152 unselected patients with chronic lymphocytic leukemia (CLL) diagnosed between 2008 and 2022 at the Kuwait Cancer Control Center, which serves as the sole cancer center in Kuwait. The evaluation of the CLL-IPI was based on the assessment of event-free survival (EFS) across the entire cohort. Subsequently, we compared the CLL-IPI with the International Prognostic Score for Early-stage patients (IPS-E) in order to predict the time to first treatment specifically within the subgroup of patients diagnosed with early-stage disease.
Results: The median age of the study cohort was 59.9 years (IQR, 53.1-68.8). The 5-year EFS rates for the low, intermediate, and high/very high-risk categories were approximately 82%, 34%, and 23%, respectively, p < 0.001 (C-statistic = 0.67). On multivariate analysis, advanced stage and unmated IGHV status were independent prognostic factors of EFS. In those with early-stage disease, cumulative 5-year treatment incidence rates for the low, intermediate, and high/very high-risk categories based on the CLL-IPI score were approximately 8%, 55%, and 55%, respectively, p = 0.001 (C-statistic = 0.70). However, based on the IPS-E score, the cumulative 5-year treatment incidence rates for the low, intermediate, and high-risk categories were approximately 0%, 10%, and 60%, respectively, p < 0.001 (C-statistic = 0.73).
Conclusions: The CLL-IPI and the IPS-E are valid stratification tool in our young Middle Eastern population.
(© 2023 The Author(s). Published by S. Karger AG, Basel.)
References: Blood. 2020 May 21;135(21):1859-1869. (PMID: 32267500)
Int J Hematol Oncol. 2017 Dec;6(4):105-111. (PMID: 30302231)
Leukemia. 2009 Jan;23(1):212-4. (PMID: 18818700)
Zhonghua Xue Ye Xue Za Zhi. 2018 May 14;39(5):392-397. (PMID: 29779348)
Am J Hematol. 2022 May;97(5):E176-E180. (PMID: 35170793)
Biomed Res Int. 2018 Mar 15;2018:9506979. (PMID: 29736400)
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):834-839. (PMID: 34788923)
Haematologica. 2018 Jul;103(7):e300-e303. (PMID: 29519862)
Haematologica. 2018 Jul;103(7):e329. (PMID: 29970494)
Lancet Oncol. 2016 Jun;17(6):779-790. (PMID: 27185642)
Blood. 2016 Oct 27;128(17):2181-2183. (PMID: 27605511)
Ann Hematol. 2019 Feb;98(2):437-443. (PMID: 30338367)
Blood. 2014 Jul 3;124(1):49-62. (PMID: 24797299)
Blood Adv. 2022 Jun 28;6(12):3716-3728. (PMID: 35468622)
Cancer. 1981 Jul 1;48(1):198-206. (PMID: 7237385)
Am J Hematol. 2016 Nov;91(11):1090-1095. (PMID: 27465919)
Br J Haematol. 2021 Apr;193(1):133-137. (PMID: 33280081)
Blood Adv. 2022 Nov 8;6(21):5698-5701. (PMID: 35090168)
Cell. 2019 Jul 25;178(3):699-713.e19. (PMID: 31280963)
Blood. 2021 Jul 15;138(2):149-159. (PMID: 33876228)
Leuk Res. 2021 Nov;110:106668. (PMID: 34492597)
Blood. 2009 Jul 30;114(5):957-64. (PMID: 19414856)
Br J Haematol. 2019 Nov;187(3):307-318. (PMID: 31243771)
Blood. 2016 Oct 20;128(16):2093-2095. (PMID: 27549308)
Blood. 2018 Jan 18;131(3):365-368. (PMID: 29084773)
فهرسة مساهمة: Keywords: CLL-IPI; IGHV status; IPS-E; Kuwait; Prognostic index
تواريخ الأحداث: Date Created: 20230730 Date Completed: 20231010 Latest Revision: 20240927
رمز التحديث: 20240927
مُعرف محوري في PubMed: PMC10601689
DOI: 10.1159/000533284
PMID: 37517397
قاعدة البيانات: MEDLINE
الوصف
تدمد:1423-0151
DOI:10.1159/000533284